ReviewFrontiers in endocrinology2025
Protein-bound uremic toxins as therapeutic targets for cardiovascular, kidney, and metabolic disorders.
Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Fruits, Vegetables, and Legumes: Harnessing the Gut-Kidney Axis in Hypertensive Chronic Kidney Disease.Foods (Basel, Switzerland) · 2026Review
- Review
- Article
- Development of an interpretable machine learning model for predicting new-onset atrial fibrillation in patients with sepsis-associated acute kidney injury: A retrospective cohort study.Science progress · 2026Article
- The association between modified cardiometabolic index and cardiovascular disease risk in adults with early cardiovascular-kidney-metabolic syndrome: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- Machine learning-based prediction of post-thrombotic syndrome in unprovoked lower extremity deep vein thrombosis: a two-center study incorporating uric acid and clinical risk factors.European journal of medical research · 2026Article
- Effects of different protein sources on rumen fermentation-microbial characteristics, nutrient utilization, and fecal and urinary metabolites in periparturient breeding cows.Frontiers in microbiology · 2026Article
- Plumericin Modulates the AhR-NFκB-Nrf2 Signaling Network to Counteract Indoxyl Sulfate-Induced Intestinal Epithelial Cells Impairment.International journal of molecular sciences · 2025Article
- Prognostic nutritional index predicts staging and mortality in cardiovascular-kidney-metabolic syndrome.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome is a systemic clinical condition characterized by pathological and physiological interactions among metabolic abnormalities, chronic kidney disease, and cardiovascular diseases, leading to multi-organ dysfunction and a higher incidence of cardiovascular endpoints. Traditional approaches to managing CKM syndrome risk are inadequate in these patients, necessitating strategies targeting specific CKM syndrome risk factors. Increasing evidence suggests that addressing uremic toxins and/or pathways induced by uremic toxins may reduce CKM syndrome risk and treat the disease. This review explores the interactions among heart, kidney, and metabolic pathways in the context of uremic toxins and underscores the significant role of uremic toxins as potential therapeutic targets in the pathophysiology of these diseases. Strategies aimed at regulating these uremic toxins offer potential avenues for reversing and managing CKM syndrome, providing new insights for its clinical diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.